FDA-approved cancer therapies

Create PDF

The FDA granted accelerated approval to nivolumab (Opdivo, Bristol-Myers Squibb) for patients with metastatic small cell lung cancer with progression after platinum-based chemotherapy and at least one other line of therapy. Approval was based on demonstration of a durable overall response rate in a subgroup of patients from CheckMate-032, a multicenter, open-label trial in patients with metastatic solid tumors. This subgroup comprised 109 patients with metastatic SCLC, with disease progression after platinum-based therapy, and at least one other prior line of therapy, regardless of tumor PD-L1 status.